嵌合抗原受体-T细胞免疫治疗B细胞恶性肿瘤的生物标志物可评估治疗疗效和毒性  

Biomarkers for chimeric antigen receptor T cell therapy in B cell malignancies can assess therapeutic efficacy and toxicity

作　　者：佟川[1] 王瑶[1] 韩为东[1] Tong Chuan;Wang Yao;Han Weidong(Department of Bio-therapeutic,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心生物治疗科,北京100853

出　　处：《中华检验医学杂志》2022年第8期875-880,共6页Chinese Journal of Laboratory Medicine

摘　　要：经过近二十年的发展,嵌合抗原受体(CAR)-T细胞在治疗血液系统恶性肿瘤中取得了巨大的临床成功。随着CAR-T细胞免疫治疗在多中心临床试验和商业化治疗中的广泛应用,疗效监测和毒性管理对于确保安全性和提高总体生存率必不可少。生物标志物不仅可以作为反映患者基线特征、肿瘤生物学特性和CAR-T细胞功能的指标,还可以评估治疗期间的毒副作用。Chimeric antigen receptor(CAR)-T cell immunotherapy have developed for nearly two decades and achieved great clinical success in the treatment of hematological malignancies.Efficacy monitoring and toxicity management of CAR-T cell immunotherapy are essential steps to ensure safety and improve overall survival in multicenter clinical trials and commercialized treatments.CAR-T cell immunotherapy related biomarkers can be used as an indicator of patient baseline characteristics,tumor biology,and CAR-T cell function.Besides,side effects during treatment can also be assessed by the biomarkers.

关 键 词：白血病 B细胞 嵌合抗原受体 生物标志物 疗效监测 

分 类 号：R733.1[医药卫生—肿瘤]